Ariana™ Pharma Receives EUR 1 Million from OSEO for IMAkinib Oncology Biomarker Program
News Oct 20, 2009
Ariana™ Pharma announces that the company is to receive EUR 1 million from France's innovation agency, OSEO, as part of the IMAkinib program. IMAkinib is a collaborative program to develop biomarkers for oncology. By playing a key role in IMAkinib, Ariana™ will be able to further develop its KEM® (Knowledge Extraction Management) technology and enter a new field, imaging biomarkers.
Cancer is still growing fast in terms of incidence, mortality rates and associated costs. WHO estimates that cancer-related deaths will climb 51 percent between 2002 and 2030 with approximately 11.5 million deaths linked to this pathology in 2030 worldwide. IMAkinib aims to improve oncology treatments by developing a new generation of specific biomarkers for diagnostics and targeted therapies.
The project leader is oncology specialist Oncodesign, and the other team member is Guerbet, responsible for radiotracers and clinical trials. The total cost of the program is estimated at EUR 24.7 million over eight years. OSEO will contribute EUR 10.3 million.
The exhaustive analysis of data allowing the selection and optimization of sensitive and specific biomarkers remains a major limiting factor on progress of current work in the field of biomarkers. The systematic analysis technology in KEM®, developed by Ariana™, could have a significant impact by overcoming the restrictions inherent in classic statistical analyzes.
Apart from the IMAkinib program itself, this project will allow Ariana™ to develop its expertise by extending the application of its KEM® technology to the field of in vivo biomarkers.
In the IMAkinib project, Ariana™ will contribute towards the multi-objective optimization of radiotracers and the selection of best candidates. Thanks to its proprietary tool, KEM®, Ariana™ can shorten the time needed to develop biomarkers and thereby reduce costs. The automatic exhaustive detection of possible biomarkers enables a better selection and a lessening of the risks linked to the choice of tracers.
"Ariana™'s inclusion in this program is important as it will build even more power and reliability into our decision support technology KEM® developed over the last several years," said Mohammad Afshar, CEO of Ariana™ Pharma. "The results of the IMAkinib program will allow Ariana™ to rapidly establish itself as a leading player in the market for biomarker development tools."
The collaboration will enable Ariana™ to offer its customers KEM® Biomarkers to accelerate their development. In addition, the automation and exhaustivity of the data analysis possible though KEM® will lead to an optimal selection of biomarkers.
"IMAkinib represents a major growth opportunity for Ariana™ and opens a new application area for our multi-objective data analysis technology KEM® to develop biomarkers in vivo," added Afshar. "We are delighted to be working alongside Guerbet and Oncodesign and to bring to the consortium our cutting edge technologies in data analysis and drug development."
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.